SCHEMBL2761706

SCHEMBL2761706

COC(=O)c1c(O)c2c(OCCCC3CCCC3)cccc2oc1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
TP53 P04637 2/20 0.46
HTT P42858 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 1/20 0.42
CRHBP P24387 1/20 0.42
KMT2A Q03164 1/20 0.42
CRHR2 Q13324 1/20 0.42
NQO1 P15559 1/20 0.41
CYSLTR2 Q9NS75 1/20 0.38
CYSLTR1 Q9Y271 1/20 0.38
NMT2 O60551 3/20 0.38
NMT1 P30419 3/20 0.38
ADRB2 P07550 2/20 0.38
ADRB1 P08588 2/20 0.38
ADRB3 P13945 2/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2761700 0.84 LMNA (0.43) LMNATP53HTTTSHRMAPK1
SCHEMBL2761741 0.84 LMNA (0.41) LMNATP53HTTTSHRMAPK1
SCHEMBL2761742 0.84 LMNA (0.41) LMNATP53HTTTSHRMAPK1
SCHEMBL2761902 0.80 MEN1 (0.44) LMNATP53HTTMEN1CRHBP
SCHEMBL2761617 0.76 EDNRA (0.54) LMNASMN1; SMN2L3MBTL1NQO1ALDH1A1
SCHEMBL2761558 0.74 EDNRA (0.46) LMNAL3MBTL1NQO1ALDH1A1
SCHEMBL2762251 0.74 BRD4 (0.47) LMNAL3MBTL1MEN1KMT2ANQO1
SCHEMBL27582279 0.72 CA12 (0.56) LMNATP53TSHRMAPK1MEN1
SCHEMBL2761629 0.68 LMNA (0.47) LMNATP53HTTTSHRMAPK1
SCHEMBL8491627 0.68 NQO1 (0.51) LMNAHTTTSHRL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 LMNA 2624/4885TP53 1014/4885HTT 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.